Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last kr75.25 SEK
Change Today -0.25 / -0.33%
Volume 121.6K
As of 11:29 AM 08/27/15 All times are local (Market data is delayed by at least 15 minutes).

medivir ab-b shs (MVIRB) Snapshot

Previous Close
Day High
Day Low
52 Week High
09/8/14 - kr131.13
52 Week Low
06/30/15 - kr69.00
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for MEDIVIR AB-B SHS (MVIRB)

Related News

No related news articles were found.

medivir ab-b shs (MVIRB) Related Businessweek News

No Related Businessweek News Found

medivir ab-b shs (MVIRB) Details

Medivir AB, a research-based pharmaceutical company, develops and sells pharmaceuticals for the treatment of infectious diseases, osteoarthritis, neuropathic pain, and oncology in the Nordic region. It focuses on the research and development of pharmaceuticals primarily in the hepatitis C area; osteoarthritis; neuropathic pain; respiratory syncytial virus; and HIV/AIDS. The company sells 16 prescription pharmaceuticals under various brands, including Mollipect, Citodon, Digoxin BioPhausia, Egazil, Laxabon, Lithionit, Morfin Special, Nitroglycerin BioPhausia, Paraflex, Probecid, Solvezink, Suscard, Teovent, and Theo-Dur. It has a collaboration agreement with Cancer Research Technology to develop cancer drugs. Medivir AB is headquartered in Stockholm, Sweden.

138 Employees
Last Reported Date: 08/20/15

medivir ab-b shs (MVIRB) Top Compensated Officers

Chief Executive Officer and President
Total Annual Compensation: kr1.9M
Compensation as of Fiscal Year 2014.

medivir ab-b shs (MVIRB) Key Developments

Medivir Announces Start of Phase I Clinical Trial of the Nucleotide Polymerase Inhibitor Al-704 for Treatment of Hepatitis C

Medivir AB announced the start of a phase I clinical trial with AL-704, also known as JNJ-54257099, by Alios Biopharma Inc., part of the Janssen Pharmaceutical Companies. AL-704 is a nucleotide based NS5B polymerase inhibitor intended for the treatment of chronic hepatitis C virus (HCV) infection in combination with other direct acting antiviral agents. Medivir entered a Research & Development agreement in the field of HCV polymerase with Janssen Products LP in May 2008. AL-704 is the second candidate drug under this agreement that enters into clinical development, and thus no additional milestone payment is due for this specific step of development. This phase I study is a randomized, double-blind, placebo-controlled, 3-part study of orally administered AL-704 to evaluate the safety, tolerability, and pharmacokinetics of single ascending doses (Part 1) and food-effect (Part 2) in healthy volunteers, and multiple doses (7 days) in subjects with chronic hepatitis C infection of genotype 1 and 3 (Part 3).

Medivir AB Reports Sales Results for the Second Quarter of 2015

Medivir AB reported sales results for the second quarter of 2015. For the second quarter of 2015, the company's total global net sales of USD 264 million against USD 832 million a year ago.

Medivir AB Enters into Partnership with GVK Biosciences Private Limited to Deliver Enhanced Efficiency and Quality within its Portfolio of Research Projects

Medivir AB announced that it has entered into a partnership with GVK Biosciences Private Ltd. to deliver enhanced efficiency and quality within its portfolio of research projects, reduce the overall research costs and enhance future cost flexibility. The partnership will consolidate and strengthen all current outsourced synthetic chemistry projects in a single facility at GVK BIO's integrated discovery research campus at Hyderabad, where an addition of approximately 20 scientific staff will further accelerate the synthesis and testing of compounds. Medivir also announced reorganization within its discovery research department, increasing its focus within the core areas of oncology and infectious diseases. The company has decided to exit the neuropathic pain area, following adverse findings in non-clinical safety studies of MIV-247, its Cathepsin S inhibitor being developed for neuropathic pain. The development of this program has been terminated and future drug discovery efforts will be focused in the core areas of oncology and infectious diseases.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MVIRB:SS kr75.25 SEK -0.25

MVIRB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for MVIRB.
View Industry Companies

Industry Analysis


Industry Average

Valuation MVIRB Industry Range
Price/Earnings 3.5x
Price/Sales 1.5x
Price/Book 1.4x
Price/Cash Flow 3.1x
TEV/Sales 0.7x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MEDIVIR AB-B SHS, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at